Cerebrospinal Fluid Metabolites and Multiple Sclerosis: Genetic Clues to Disease Risk

Multiple sclerosis (MS) is a chronic neurological disorder characterized by inflammatory and neurodegenerative processes that can lead to sensory impairment, impaired mobility, sphincter dysfunction, recurrent neurological episodes, and progressive disability. Despite substantial advances in immunology and genetics, the biological mechanisms responsible for MS remain incompletely understood, creating a continuing need for biomarkers that can illuminate disease pathways and potentially guide prevention or treatment. In the study Cerebrospinal Fluid Metabolites and Multiple Sclerosis: A Two-Sample Mendelian Randomization Study, Zhang and colleagues investigated whether metabolic compounds present in cerebrospinal fluid (CSF) might have a causal relationship with susceptibility to MS. CSF is particularly valuable for this purpose because it directly surrounds the brain and spinal cord and therefore provides a biochemical window into the central nervous system. Previous research had already identified abnormal CSF concentrations of molecules such as glycine and L-glutamate in individuals with MS, but conventional observational studies cannot easily determine whether such abnormalities contribute to the disease or merely arise as consequences of it. The authors therefore attempted to move beyond correlation by examining genetically predicted differences in CSF metabolites and their relationship with MS risk.

Mendelian Randomization as a Strategy for Investigating Causality
The central methodological feature of the study was two-sample Mendelian randomization (MR), an epidemiological approach that uses inherited genetic variants as instrumental variables to estimate whether an exposure may causally influence an outcome. Because genetic variants are allocated at conception, MR can reduce some forms of confounding and reverse causation that complicate conventional observational research. The study evaluated genetic predisposition to hundreds of CSF metabolites in relation to MS risk. As illustrated by the methodological diagram on page 2, valid MR analysis depends on three principal assumptions: the genetic instruments must be associated with the metabolite exposure, they should not be associated with relevant confounding factors, and they should influence MS only through the metabolite being investigated. The investigators selected single-nucleotide polymorphisms associated with metabolites at a threshold of P < 5 × 10⁻⁵, removed variants in strong linkage disequilibrium, and excluded weak instruments using an F-statistic threshold of 10. The primary causal estimates were generated with random-effects inverse-variance weighting, while weighted-median, MR-Egger, weighted-mode, MR-PRESSO, heterogeneity testing, and leave-one-out analyses were employed as sensitivity procedures. These complementary techniques were intended to test whether the observed associations could instead be explained by pleiotropy, heterogeneity, or disproportionately influential genetic variants.

Large MS Genetic Data Contrasted With a Smaller CSF Metabolomic Dataset
The analysis combined two independent genome-wide association study resources. Genetic associations with CSF metabolites were derived from 689 participants recruited through the Wisconsin Alzheimer Disease Research Center and Wisconsin Registry for Alzheimer’s Prevention, with participants reported as being of European ancestry. CSF samples were obtained by lumbar puncture using standardized collection and storage procedures. The MS outcome dataset was considerably larger, incorporating 115,803 participants, including 47,429 individuals with MS and 68,374 controls, also of European ancestry. This difference in scale is scientifically important: the large MS dataset provides substantial information regarding genetic susceptibility to the disease, whereas the comparatively small metabolomic dataset limits the precision with which genetic determinants of CSF metabolites can be estimated. The paper predominantly describes the investigation as covering 338 CSF metabolites, although one passage in the Results section reports 388 exposures, representing an internal numerical inconsistency that should be acknowledged rather than silently reconciled. The authors additionally applied false discovery rate correction to address the problem of multiple statistical comparisons. Under their predefined criteria, associations with P < .05 but an FDR-adjusted P value of at least .05 were categorized as suggestive rather than formally significant, an important distinction when interpreting the biological implications of the findings.

Metabolites Genetically Associated With Increased Multiple Sclerosis Risk
Among the most prominent findings were three CSF metabolites associated with higher predicted MS risk: beta-alanine, 1-stearoyl-2-arachidonoyl-GPC (18:0/20:4), and allantoin. For beta-alanine, the inverse-variance weighted estimate produced an odds ratio of 1.248, corresponding to an approximately 24.8% higher MS risk per standard-deviation increase in genetically predicted metabolite level. The corresponding odds ratios were 1.090 for 1-stearoyl-2-arachidonoyl-GPC and 1.123 for allantoin, representing estimated increases in risk of approximately 9% and 12.3%, respectively. The forest plot presented on page 3 places these associations alongside the broader set of metabolite estimates and their confidence intervals. Biologically, the lipid 1-stearoyl-2-arachidonoyl-GPC is particularly intriguing because it contains arachidonic acid and can participate in phospholipid turnover. The authors note that cleavage of arachidonic-acid-rich phospholipids can generate mediators relevant to neuroinflammatory signaling, while lysophosphatidylcholine products may promote microglial activation. Allantoin, by contrast, is linked to oxidative biology: in humans it can arise through reactive-oxygen-species-mediated oxidation of uric acid, making it a potential indicator of oxidative stress. Its positive association with MS is therefore consistent with established roles of oxidative injury in demyelination, mitochondrial dysfunction, and axonal damage, although the authors also acknowledge previous CSF research that did not demonstrate increased urate oxidation to allantoin in MS.

Potentially Protective Associations of TMAP, Butyrate, and N-Acetylglycine
The study also identified three metabolites whose genetically predicted increases were associated with lower MS risk: N,N,N-trimethyl-L-alanyl-L-proline betaine (TMAP), butyrate (4:0), and N-acetylglycine. The reported odds ratios were 0.934 for TMAP, 0.908 for butyrate, and 0.909 for N-acetylglycine, corresponding to estimated risk reductions of approximately 6.6%, 9.2%, and 9.1% per standard-deviation increase, respectively. These observations raise potentially important biological questions, but the underlying mechanisms remain uncertain. The biological origin of TMAP is not fully established, and the authors emphasize that additional research is required to clarify its physiological role. N-acetylglycine is a glycine derivative generated through metabolic processes in several organs, yet its relevance to MS has not been well characterized, making its apparently protective association a hypothesis requiring independent validation. Butyrate is arguably the most biologically interpretable of the three because previous experimental work has described neuroprotective properties of sodium butyrate in neurological disease models. The authors therefore suggest that butyrate-related pathways may deserve closer attention in MS. Nevertheless, MR findings concern genetically predicted long-term differences in metabolite levels and should not be interpreted as evidence that simply administering or increasing these compounds would necessarily prevent disease.

Statistical Robustness Does Not Eliminate Biological and Design Limitations
A notable strength of the investigation was its extensive sensitivity analysis. MR-Egger testing did not indicate horizontal pleiotropy, Cochran’s Q analyses did not identify substantial heterogeneity, MR-PRESSO was used to identify and remove outlying variants, and leave-one-out analyses did not suggest that the principal estimates were driven by individual SNPs. Furthermore, the F-statistics for the genetic instruments exceeded 10, reducing concern regarding classical weak-instrument bias. These features strengthen confidence that the reported associations are not obvious artifacts of a single analytical assumption. However, they do not transform suggestive statistical evidence into definitive biological proof. The metabolomic GWAS included only 689 individuals, which the authors themselves recognize as a major reason for cautious interpretation and a need for larger CSF-specific genomic datasets. An additional limitation is ancestry: the exposure and outcome datasets were derived from European populations, so the results cannot automatically be generalized to populations with different genetic architectures, metabolomic profiles, or MS susceptibility patterns. The use of a relatively permissive SNP-selection threshold of P < 5 × 10⁻⁵ also reflects the practical challenge of identifying sufficient genetic instruments for CSF metabolites. Finally, because hundreds of metabolites were assessed simultaneously and the paper distinguishes FDR-confirmed findings from merely suggestive associations, replication remains essential before these metabolites can be regarded as established causal determinants of MS.

From Metabolic Associations to Future Multiple Sclerosis Research
The broader significance of this study lies in its attempt to connect central nervous system metabolism with the causal architecture of multiple sclerosis. By integrating CSF metabolomics with large-scale human genetic data, the analysis highlights beta-alanine, 1-stearoyl-2-arachidonoyl-GPC, allantoin, TMAP, butyrate, and N-acetylglycine as candidates for deeper mechanistic investigation. These compounds point toward several potentially relevant biological domains, including amino-acid metabolism, phospholipid remodeling, oxidative stress, neuroinflammatory signaling, and metabolic regulation of neural function. The findings may eventually contribute to biomarker development or identification of therapeutic pathways, but the evidence remains at an early stage. The authors conclude that interventions directed toward CSF metabolites might have preventive potential, while simultaneously emphasizing that the underlying mechanisms require further investigation. A scientifically cautious interpretation is therefore that this study provides genetically informed hypotheses rather than immediately actionable clinical targets. Future work should replicate the associations in larger CSF metabolomic GWAS datasets, test them across diverse ancestral populations, examine the biochemical pathways linking these metabolites to immune and neurodegenerative processes, and determine whether experimentally manipulating relevant pathways modifies MS-related pathology. If such evidence converges, CSF metabolomics could become an increasingly important bridge between genetic susceptibility, molecular mechanisms, and more precise strategies for understanding or eventually preventing multiple sclerosis.

Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.

References:
Zhang, D., Feng, J., Feng, J., & Chen, G. (2026). Cerebrospinal fluid metabolites and multiple sclerosis: A two-sample Mendelian randomization study. Medicine, 105(1), e46960. https://doi.org/10.1097/MD.0000000000046960